Error message

EDS Server Issue
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Online Access: Xie Y, Minna JD, Xie Yang, Minna John D. A lung cancer molecular prognostic test ready for prime time. (LANCET) 3/3/2012; 379 (9818): 785-787 <span>(108170227)</span>
    • Subject Terms:
    • Subject Terms:
    • Abstract:
      Background: The frequent recurrence of early-stage non-small-cell lung cancer (NSCLC) is generally attributable to metastatic disease undetected at complete resection. Management of such patients depends on prognostic staging to identify the individuals most likely to have occult disease. We aimed to develop and validate a practical, reliable assay that improves risk stratification compared with conventional staging.Methods: A 14-gene expression assay that uses quantitative PCR, runs on formalin-fixed paraffin-embedded tissue samples, and differentiates patients with heterogeneous statistical prognoses was developed in a cohort of 361 patients with non-squamous NSCLC resected at the University of California, San Francisco. The assay was then independently validated by the Kaiser Permanente Division of Research in a masked cohort of 433 patients with stage I non-squamous NSCLC resected at Kaiser Permanente Northern California hospitals, and on a cohort of 1006 patients with stage I-III non-squamous NSCLC resected in several leading Chinese cancer centres that are part of the China Clinical Trials Consortium (CCTC).Findings: Kaplan-Meier analysis of the Kaiser validation cohort showed 5 year overall survival of 71·4% (95% CI 60·5-80·0) in low-risk, 58·3% (48·9-66·6) in intermediate-risk, and 49·2% (42·2-55·8) in high-risk patients (p(trend)=0·0003). Similar analysis of the CCTC cohort indicated 5 year overall survivals of 74·1% (66·0-80·6) in low-risk, 57·4% (48·3-65·5) in intermediate-risk, and 44·6% (40·2-48·9) in high-risk patients (p(trend)<0·0001). Multivariate analysis in both cohorts indicated that no standard clinical risk factors could account for, or provide, the prognostic information derived from tumour gene expression. The assay improved prognostic accuracy beyond National Comprehensive Cancer Network criteria for stage I high-risk tumours (p<0·0001), and differentiated low-risk, intermediate-risk, and high-risk patients within all disease stages.Interpretation: Our practical, quantitative-PCR-based assay reliably identified patients with early-stage non-squamous NSCLC at high risk for mortality after surgical resection.Funding: UCSF Thoracic Oncology Laboratory and Pinpoint Genomics.
    • Journal Subset:
      Biomedical; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland
    • ISSN:
      0099-5355
    • MEDLINE Info:
      PMID: NLM22285053 NLM UID: 2985213R
    • Grant Information:
      R01 CA132566/CA/NCI NIH HHS/United States; R01 CA132566-05/CA/NCI NIH HHS/United States
    • Publication Date:
      20120330
    • Publication Date:
      20200708
    • PubMed Central ID:
      PMC3294002
    • DOI:
      10.1016/S0140-6736(11)61941-7
    • Accession Number:
      108170222
  • Citations
    • ABNT:
      KRATZ JR et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet, [s. l.], v. 379 North American Edition, n. 9818, p. 823–832, 2012. DOI 10.1016/S0140-6736(11)61941-7. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=108170222. Acesso em: 26 set. 2020.
    • AMA:
      Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012;379 North American Edition(9818):823-832. doi:10.1016/S0140-6736(11)61941-7
    • APA:
      Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, & Segal MR. (2012). A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet, 379 North American Edition(9818), 823–832. https://doi.org/10.1016/S0140-6736(11)61941-7
    • Chicago/Turabian: Author-Date:
      Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, et al. 2012. “A Practical Molecular Assay to Predict Survival in Resected Non-Squamous, Non-Small-Cell Lung Cancer: Development and International Validation Studies.” Lancet 379 North American Edition (9818): 823–32. doi:10.1016/S0140-6736(11)61941-7.
    • Harvard:
      Kratz JR et al. (2012) ‘A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies’, Lancet, 379 North American Edition(9818), pp. 823–832. doi: 10.1016/S0140-6736(11)61941-7.
    • Harvard: Australian:
      Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC & Segal MR 2012, ‘A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies’, Lancet, vol. 379 North American Edition, no. 9818, pp. 823–832, viewed 26 September 2020, .
    • MLA:
      Kratz JR, et al. “A Practical Molecular Assay to Predict Survival in Resected Non-Squamous, Non-Small-Cell Lung Cancer: Development and International Validation Studies.” Lancet, vol. 379 North American Edition, no. 9818, Mar. 2012, pp. 823–832. EBSCOhost, doi:10.1016/S0140-6736(11)61941-7.
    • Chicago/Turabian: Humanities:
      Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, et al. “A Practical Molecular Assay to Predict Survival in Resected Non-Squamous, Non-Small-Cell Lung Cancer: Development and International Validation Studies.” Lancet 379 North American Edition, no. 9818 (March 3, 2012): 823–32. doi:10.1016/S0140-6736(11)61941-7.
    • Vancouver/ICMJE:
      Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet [Internet]. 2012 Mar 3 [cited 2020 Sep 26];379 North American Edition(9818):823–32. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=108170222